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Abstract
Background: A rapid and specific test is urgently needed for tuberculosis (TB) diagnosis especially among human
immunodeficiency virus (HIV) infected individuals. In this study, we assessed the sensitivity of Interferon gamma release
assay (IGRA) in active tuberculosis patients who were positive for HIV infection and compared it with that of tuberculin skin
test (TST).
Methodology/Principal Findings: A total of 105 HIV-TB patients who were naı¨ve for anti tuberculosis and anti retroviral
therapy were included for this study out of which 53 (50%) were culture positive. Of 105 tested, QuantiFERON-TB Gold in-
tube (QFT-G) was positive in 65% (95% CI: 56% to 74%), negative in 18% (95% CI: 11% to 25%) and indeterminate in 17%
(95% CI: 10% to 24%) of patients. The sensitivity of QFT-G remained similar in pulmonary TB and extra-pulmonary TB
patients. The QFT-G positivity was not affected by low CD4 count, but it often gave indeterminate results especially in
individuals with CD4 count ,200 cells/ml. All of the QFT-G indeterminate patients whose sputum culture were positive,
showed#0.25 IU/ml of IFN-c response to phytohemagglutinin (PHA). TST was performed in all the 105 patients and yielded
the sensitivity of 31% (95% CI: 40% to 22%). All the TST positives were QFT-G positives. The sensitivity of TST was decreased,
when CD4 cell counts declined.
Conclusions/Significance: Our study shows neither QFT-G alone or in combination with TST can be used to exclude the
suspicion of active TB disease. However, unlike TST, QFT-G yielded fewer false negative results even in individuals with low
CD4 count. The low PHA cut-off point for indeterminate results suggested in this study (#0.25 IU/ml) may improve the
proportion of valid QFT-G results.
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Introduction
Tuberculosis (TB) remains the single infectious disease, causing
the highest mortality in humans, leading to 3 million deaths
annually. Approximately 8–10 million people are infected with this
pathogen every year [1]. The vast majority of TB cases are reported
in Africa, South East Asia and Western Pacific countries. The recent
increase in the number of cases even in developed countries,
associated with the spread of human immunodeficiency virus (HIV)
infection, has had a major impact on the current situation of TB.
India accounts for a huge number of HIV-TB cases and ranks first
in the world in terms of incident of TB cases. [2].
Individuals with HIV infection are at increased risk of rapid
progression of a recently acquired tuberculous infection, as well as
of re-activation of latent TB infection (LTBI). Delayed diagnosis of
TB and initiation of appropriate treatment more than 3 weeks
after presentation, are associated with 45–85% of deaths in HIV
infected patients [3]. Early diagnosis and prompt treatment for TB
are the key elements to control the mortality rate of HIV infected
subjects. The clinical features of HIV-infected patients with TB
are often non-specific. Decreased tuberculin reactivity, lower
sensitivity of acid fast staining, atypical radiographic presentations,
and similarity in presentation with other HIV related infections
hinder the diagnosis of TB in HIV infected patients [4].
Recently introduced Interferon gamma release assays (IGRA) are
promising tests for the diagnosis of TB infection. IGRA is available in
two commercial formats: (i) Quantiferon TB Gold (QFT-G) (Cellestis
Ltd, Victoria, Australia), which measures the quantity of IFN-c
secreted by T cells and (ii) T-Spot.TB assay (Oxford Immunotech,
Oxford, UK) which enumerates the number of IFN-c secreting T
cells after in vitro stimulation with TB-specific antigens. T-Spot.TB
assay uses only Early Secreted Antigen Target (ESAT)-6 and Culture
filtrate protein (CFP)-10, whereas an additional antigen TB7.7 is
incorporated in Quantiferon TB Gold. Several studies have been
conducted in various clinical settings on the accuracy and utility of
IGRA and these have been reviewed elsewhere [5]. Most of these
studies have reported that sensitivity of IGRA is modest to detect
active TB disease [6–12] and also suggested that IGRA alone [13,14]
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or in combination with TST [15] can be used to exclude the suspicion
of active TB disease. Nevertheless, in general there is a concern about
the sensitivity of IGRA in immunosuppressed (especially HIV)
patients, as these assays are T-cell based whose number is often
compromised in these patients [16]. Only a very few studies have
been conducted on IGRA assays in immunocompromised patients,
especially from TB endemic countries [17,18], emphasizing the need
for more such studies to test the validity of the IGRA assays in such
settings. Hence, in this study, we aimed to measure the sensitivity of
IGRA in diagnosing of active TB among HIV positive subjects in a
country like India where both the diseases are co-existing and are
endemic.
Materials and Methods
This study was approved by the Scientific Advisory Committee
and Institutional Ethical Committee of Tuberculosis Research
Centre, Chennai. A written and informed consent was obtained
from all the study participants before drawing blood.
Study subjects recruitment
The recruitment of study subjects were done at Government
Hospital of Thoracic Medicine, Tambaram, Chennai during April
2007 and March 2008. The demographic details and information
on previous tuberculin skin test (TST) results were collected.
Individuals with previous history of TB, silicosis, end stage renal
disease, leukemia/lymphoma, who had TST in the past 16
months, under ATT for more than two weeks or ART or
immunosuppressive therapy were excluded from the study.
Pregnant and lactating patients were also excluded.
After registering the eligible patients, the radiological examination
was carried out. A total of six sputum samples were collected from
each study subject and they were stained for acid fast bacilli (AFB)
microscopy. The staining for acid fast bacilli was done by Ziehl-
Neelsen method [19]. Three sputum samples of each subject were
cultured in conventional Lowenstein Jensen (Biomerieux Inc., Marcy
I’Etoile, France) and also in liquid MP BacT medium (Biomerieux
Inc., Marcy I’Etoile, France). The presence of M. tuberculosis in the
positive culture samples was further confirmed by Gen-probe based
PCR (Biomerieux Inc, Marcy I’Etoile, France) method.
The presence of active TB was defined as positive for sputum
smear microscopy and/or identification of M. tuberculosis in sputum
culture and/or abnormality suggestive of TB in chest x-ray. In
addition, Fine Needle Aspiration Cytology (FNAC) was carried out
in the individuals with extra pulmonary manifestations who were
clinically suspected but had negative sputum results and normal
chest x-ray. The diagnosis of pulmonary TB for the individuals
with culture and smear negativity was based on chest x-ray finding
and the clinician’s opinion based on the clinical manifestations.
Blood was drawn from all the HIV-TB patients for total blood
count, HIV serology and QFT-G. Then the TST was carried out.
After the diagnosis, the patients were referred to respective
treatment centers.
HIV testing
The HIV status was confirmed by 2 rapid tests (Retroquic Comb
Aids-RS, Span Diagnostics, India and HIV TRI-DOT, J. Mitra &
Co, India). When a serum was positive for both tests, it was
considered as HIV positive. If a serum was positive for only one EIA
(which was rare), Western Blot was done as confirmatory test.
CD4 count
The CD4 cell count was estimated in blood samples of HIV
positive individuals by flow cytometry. 100 ml of whole blood was
labelled with saturating concentrations of anti CD3-FITC, anti CD4-
PE and anti CD8-APC (BD Biosciences, CA, USA). After 30 min
incubation at 4uC, the red blood cells were lyzed using FACS lysing
solution (BD Biosciences, CA, USA) and then fixed with 1%
paraformaldehyde (Sigma Chemicals Co., MO, USA). The acqui-
sition was done on FACS Calibur (BD Biosciences, CA, USA) and
the percentages of CD3, CD4 and CD8 cells among the total
lymphocytes were obtained using Flowjo Software (Tree star, Inc.,
CA, USA). The absolute CD3, CD4 and CD8 counts were calculated
by multiplying the percentage with the total lymphocyte count.
Interferon gamma release assay
The IFN-c release assay was performed using Quantiferon TB-
Gold In-tube (QFT-G) test (Cellestis Ltd., Victoria, Australia). One
ml of blood was taken in each of the three tubes precoated with TB–
antigen, phytohemaglutinin (PHA) for the positive control or no
antigen for the negative control. The blood samples were drawn
between 10 and 11 AM and taken to the lab within 2 hrs of
phlebotomy. The tubes were incubated for 16–24 hrs at 37uC and
plasma were collected after centrifugation and stored at 4uC until
assayed. Within two weeks of time, QFT-G enzyme linked
immunosorbant assay (ELISA) was carried out. The test results
were interpreted using the software given by the manufacturer
(Cellestis Ltd., Victoria, Australia) and the cut-off point for the
diagnosis was determined as per manufacturer’s instructions. If the
IFN-c secretion in response to TB antigen was $0.35 IU/ml, after
subtracting NIL control IFN-c, it was considered as positive for
QFT-G and if the value was ,0.35 IU/ml, it was considered as
negative. If the negativity was associated with poor PHA response
(i.e. IFN-c secretion in response to PHA, after subtracting NIL
control IFN-c was,0.5 IU/ml), it was considered as indeterminate
or invalid result for QFT-G.
Tuberculin Skin Test
The 2 TU (tuberculin unit) of purified protein derivative (PPD)
RT23 (Staten Serum Institute, Copenhagen, Denmark) was
injected intradermally by Mantoux method and the induration
was measured between 48–72 hrs after PPD injection by trained
professionals. The cut-off point for TST positivity was considered
as 5 mm for this study [20,21].
Statistical Analysis
Data were analyzed using SPSS 15.0 and Graphpad Prism 4.0
software. Mann-Whitney ‘‘U’’ test was carried out to calculate the
difference between the groups. Logistic regression analysis was
performed to examine the effect of potential variables on the odds
of presenting a positive QFT-G test response. Odds ratios (OR)
and their 95% confidence intervals (CI) were estimated by
multivariate analyses. In these analyses, continuous variables were
taken as dichotomous variables using the following arbitrary cut-
off values: Age-36 years (median of the study population) and
BMI-18.5 kg.m2. Based on the CD4 count, the patients were
classified as ,50 (Advance stage), 50–199 (AIDS defining) and
.200 cell/ml to assess QFT-G and TST results.
Results
A total of 300 HIV positive subjects were assessed during the
study period. Among them 112 (37%) were identified as HIV-TB
positive patients. 7 (6%) out of 112 patients refused to participate
in this study and hence the remaining 105 were included. Among
105 patients who all were naı¨ve for ATT and ART, 53 (50%) were
culture confirmed TB patients. The demographic and baseline
characteristics of all the 105 study subjects are given in Table 1.
IGRA on HIV-TB Diagnosis
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Sensitivity of QFT-G and TST
The results of QFT-G and TST are given in Table 2. Of 105
patients tested, 68 (65%, 95% CI: 56% to 74%) were positive and
19 (18%, 95% CI: 11% to 25%) were negative for QFT-G. The
remaining 18 (17%, 95% CI: 10% to 24%) patients showed
indeterminate results. All the indeterminate or invalid results were
due to poor response to PHA. Among the 105 patients, 33 showed
$5 mm induration for TST yielding the sensitivity of 31% (95%
CI: 22% to 40%). When comparing QFT-G and TST results, the
former was 33% more sensitive than the latter (P,0.001). None of
the TST positives were negative or indeterminate for QFT-G
(Figure 1). Among the 72 TST negatives, 50% were positive and
25% were negative for QFT-G.
In a sensitivity analysis to investigate whether inclusion of highly
probable cases (which was diagnosed based on abnormalities
found in the chest X-ray and clinician’s opinion) affected the
sensitivity of the tests, we calculated the sensitivity in culture
positive and negative cases separately. The positivity obtained in
culture positive PTB, culture negative PTB and EPTB patients
were 66% (95% CI: 52%–80%), 45% (95% CI: 24% to 66%) and
77% (95% CI: 64%–90%) for QFT-G and 25% (95% CI: 12%–
38%), 27% (95% CI: 8%–46%) and 41% (95%CI: 26%–56%) for
TST respectively. The positivity of QFT-G was significantly
higher than TST in culture positive PTB and EPTB groups
(P,0.001 and P = 0.002 respectively) but not in culture negative
PTB group (P = 0.347). The proportion of QFT-G indeterminate
results obtained in these groups was 23%, 18% and 10%
respectively.
Influence of Immunosupression on QFT-G and TST
The median total lymphocyte, CD3, CD4 and CD8 counts did
not differ significantly between QFT-G positive and negative
subjects but was significantly lower in indeterminate subjects when
compared to QFT-G positives (P = 0.0013, P = 0.003, P = 0.0418
Table 1. Demographic and baseline parameters of all the 105
HIV-TB patients.
Category Subcategory
N (%) or Median
(Range; IQR)
Sex, Number (%) Male 84 (80)
Female 21 (20)
Age, Median in years (Range; IQR) 36 (18–63; 25, 36)
BMI, kg/m2 Median (Range; IQR) 19 (13–31; 17,21)
HIV strain, Number (%) HIV-I 94 (90%)
HIV-I&II 11 (10%)
TB types, Number (%) PTB 66 (63%)
EPTB 39 (37%)
Smear, Number (%) Positives 47 (45%)
Negatives 58 (55%)
Culture, Number (%) Positives 53 (50%)
Negatives 52 (50%)
CD4, Median (Range; IQR)
(Available for 81 subjects)
116 (11–2062; 48, 209)
BMI – Body mass index.
PTB – Pulmonary tuberculosis.
EPTB- Extra-pulmonary tuberculosis.
IQR-Inter quartile range.
doi:10.1371/journal.pone.0005718.t001
Table 2. Performance of QFT-G and TST in subgroups of HIV-TB patients.
Groups QFT-G TST
% Pos (95%CI)) % Neg (95%CI) % Indt (95%CI) % Pos (95%CI) % Neg (95%CI))
Overall (N=105) 65 (56–74) 18 (11–25) 17 (10–24) 31 (22–40) 69 (60–78)
PTB (N=66) 59 (47–71) 20 (10–30) 21 (11–31) 26 (15–37) 74 (63–85)
Sputum culture positive (N=44) 66 (52–80) 11 (2–20) 23 (11–35) 25 (12–38) 75 (62–88)
Sputum culture negative (N=22) 45 (24–66) 37 (17–57) 8 (2–34) 27 (8–46) 73 (54–92)
Sputum smear positive (N=43) 68 (54–82) 9 (1–18) 23 (10–36) 26 (13–39) 74 (61–87)
Sputum Smear negative (N=23) 44 (24–64) 39 (19–59) 17 (2–32) 26 (8–44) 74 (56–92)
EPTB (N=39) 77 (64–90) 13 (2–24) 10 (1–19) 41 (25–56) 59 (44–74)
Pos – Positive.
Neg – Negative.
Indt – Indeterminate.
Sen - Sensitivity.
PTB – Pulmonary tuberculosis.
EPTB- Extra-pulmonary tuberculosis.
doi:10.1371/journal.pone.0005718.t002
Figure 1. Agreement between TST and QFT-G test results.
Among the 105 subjects tested, 72 were negative for TST. Of the 72 TST
negative, 50% were positive for QFT-G. None of the TST positive was
negative or indeterminate for QFT-G. TST-Tuberculin Skin Test, QFT-G-
Quantiferon TB Gold in-tube, Pos - Positive, Neg - Negative, Indt –
Indeterminate.
doi:10.1371/journal.pone.0005718.g001
IGRA on HIV-TB Diagnosis
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and P = 0.0221 respectively) (Figure 2). When comparing the
TST positive and negative subjects, the cell counts were
significantly lower in TST negative than positive subjects
(p = 0.0403, p = 0.0344 and P = 0.017 respectively) (Figure 3).
Further to confirm the influence of CD4 count on the positivity
of QFT-G and TST, we developed a logistic regression model
based on the CD4 counts (Table 3), for which, we stratified the
CD4 cells counts as,50 cells/ml, 51–200 cells/ml and .200 cells/
ml. When the QFT-G indeterminate results were considered as
negative, the sensitivity of the assay was impaired in subjects with
CD4 count ,200 cells/ml (P = 0.047). This trend was not
observed, if the indeterminate results were excluded (P = 0.124).
TST positivity was decreased when the CD4 cell count dropped to
,200 cells/ml, the (P = 0.04) (Table 4). The other tested
parameters HIV strain, BMI, age, sex and types of TB were not
found to influence the performance of QFT-G and TST.
QFT-G cut-off values
We analyzed the cut-off values for secretion of IFN-c in
response to TB antigens and PHA in culture confirmed TB cases.
Applying the cut-off$0.13 IU/ml for TB antigens as suggested by
Harada et al [22] to our data, did not improve the sensitivity of
QFT-G. Only one indeterminate subject became positive for
QFT-G.
A total of 36 subjects showed IFN-c secretion ,0.35 IU/ml in
response to TB antigens. Among them 18 subjects were negative
(i.e. IFN-c secretion to PHA was .0.5 IU/ml) and the remaining
18 were indeterminate (i.e. IFN-c secretion to PHA was ,0.5 IU/
ml) for QFT-G. The ranges of IFN-c levels to PHA were 0.5 to
15.23 IU/ml in QFT-G negative subjects and 0–0.39 IU/ml in
QFT-G indeterminate subjects. Of 18 indeterminate subjects, 12
(67%) showed #0.1 IU/ml IFN-c response and 16 (89%) showed
,0.25 IU/ml IFN-c response to PHA (Table 5). Interestingly, all
the culture positive HIV-TB cases who were indeterminate for
QFT-G showed ,0.25 IU/ml IFN-c response to PHA.
Discussion
Early diagnosis of the active tuberculosis disease will help in
earlier treatment, which is especially needed in HIV infected cases,
since there is an accelerated progression of TB and higher
mortality. However, there are lacunae in existing methods to
diagnose TB in HIV positive subjects, which urge the development
of alternative, rapid and accurate method. In this study, we have
assessed the sensitivity of an emerging diagnostic method, IGRA
among newly diagnosed HIV-TB patients.
QFT-G (In-tube) was recently approved by US Food and Drug
Administration (FDA) in October 2007 and is the only
commercially available IGRA test in India. Hence, in this study
we used QFT-G (in-tube) method to analyze the role of IGRA.
In this study, we found that QFT-G can detect only 65% of
active cases among the HIV infected individuals. Even in the
culture confirmed TB cases, the QFT-G sensitivity was maintained
as 66%. All the TST positives were positive for QFT-G. Hence,
combining TST with QFT-G also could not enhance the overall
sensitivity. If the indeterminate results were excluded, QFT-G
Figure 2. The level of total lymphocyte and T cell counts in QFT-G positive, negative and indeterminate subjects. The decline of total
lymphocytes (a) or CD3 count (b) or CD4 count (c) or CD8 count (d) was associated with QFT-G indeterminate only but not with QFT-G negative. Box
and Whisker plots show range, inter-quartile range and median. QFT-G – Quantiferon TB Gold (in-tube), * significant difference p,0.05, **significant
difference p,0.01 by Mann-Whitney U test.
doi:10.1371/journal.pone.0005718.g002
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showed 78% overall sensitivity and 88% sensitivity in culture
confirmed cases. Hence, we conclude that QFT-G alone or in
combination with TST cannot be used to exclude the active TB
disease among HIV infected individuals. Of note, due to the
inefficiency in discriminating the active and latent TB, the
specificity of QFT-G and TST will always be low for active TB
diagnosis in endemic countries like India (5).
The major concern in using T-cell based assay is the influence
of CD4 count on the sensitivity. In QFT-G, the overlapping
peptides of ESAT-6, CFP-10 and TB7.7 antigens are used, which
are MHC class II restricted and largely recognized by CD4 T cells.
Hence, it can be presumed that the sensitivity of QFT-G would be
affected when CD4 count drops severely. While some of the
studies showed IGRA was less influenced by HIV infection
[23,24], other study results contradict the observations [25,18].
However, in our study we did not find any significant difference in
CD4 count between QFT-G positive and negative subjects. The
logistic regression model also confirmed that QFT-G negative
results are CD4 count independent.
Another drawback of T-cell based assays is its poor sensitivity in
EPTB patients. It was reported that in EPTB patients, the
secretion of IFN-c to M. tuberculosis antigens is poorer than the
Figure 3. The level of total lymphocyte and T cell count in TST Positive and negative subjects. The level of total lymphocytes (a), CD3
count (b), CD4 count (c) were significantly low in TST negatives than TST positives whereas CD8 count (d) was not significantly different. Box and
Whisker plots show range, inter-quartile range and median. TST – Tuberculin skin test, * significant difference p,0.05 by Mann-Whitney U test.
doi:10.1371/journal.pone.0005718.g003
Table 3. Analysis of variables associated with positive QFT-G test results.
Variables With Indeterminate results Without Indeterminate results
N Odds Ratio (95%CI) P N Odds Ratio (95%CI) P
CD4 $200 81 7.058 (1.196–41.656) 0.047 70 4.596 (0.658–32.095) 0.124
Sex female 105 0.423 (0.107–1.673) 0.220 87 0.712 (0.147–3.456) 0.673
Age .36 105 1.282 (0.392–4.196) 0.681 87 0.960 (0.222–4.145) 0.956
BMI .18.5 91 1.005 (0.293–3.441) 0.994 78 1.890 (0.448–7.972) 0.386
EPTB 105 3.066 (0.765–12.284) 0.114 87 2.567 (0.564–11.691) 0.223
HIV strain I 105 1.295 (0.239–7.014) 0.764 87 0.836 (0.118–5.916) 0.858
Presence of Oral candidiasis 84 0.628 (0.150–2.625) 0.628 81 1.174 (0.203–6.783) 0.858
BMI – Body mass index.
N – Number of patients tested.
doi:10.1371/journal.pone.0005718.t003
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PTB patients [26]. Lee et al [27] reported that QFT-G is poor in
detecting EPTB cases. Dewan et al [28] have shown only 16%
sensitivity for QFT-G in EPTB patients. In contrast, we obtained
77% sensitivity using QFT-G in EPTB patients, in our study.
Exclusion of indeterminate results yielded 86% sensitivity, which is
similar to what we observed with culture confirmed PTB (88%).
Hence, we conclude that the sensitivity of QFT-G is not
compromised in EPTB when compared to PTB patients.
However, since most of the EPTB subjects in our study group
were TB lymphadenitis cases, further evidence is needed on the
sensitivity of IGRA in other forms of extra pulmonary TB.
The major disadvantage we found in using QFT-G for HIV-TB
diagnosis is the high number of QFT-G indeterminate results. In
order to rule out the technical errors, the stimulated as well as
unstimulated plasma samples which were used for QFT-G testing
were centrifuged at high speed and measured for IFN-c level once
again using QFT-G ELISA plates. However, none of the
indeterminate results became positive. The occurrence of
indeterminate results is often pointed out in earlier studies as
drawback of IGRA in TB diagnosis especially among individuals
with strong immunosuppression [29]. Ferrea et al reported that
QFT-G showed 20% indeterminate results and it was associated
with severity of immunosuppression [30]. In our study, we
observed 17% indeterminate results and all the subjects who
showed indeterminate results had CD4 count ,200 cells/ml. Our
observations corroborate Ferrara et al study results.
To improve the sensitivity and reduce the indeterminate results
of QFT-G, we re-analyzed our data with different cut-off points.
Applying the reduced cut-off point suggested by Harada et al, [22]
(0.13 IU/ml) for TB antigen specific IFN-c levels, did not improve
the QFT-G sensitivity in our study. When we analyzed the levels
of IFN-c in response to PHA, we found that all the culture
confirmed QFT-G indeterminate subjects secreted IFN-c in the
range of 0–0.25 IU/ml and in particular most of the subjects
showed #0.10 IU/ml.
A valid and lower cut-off point for PHA is required to overcome
the misclassification of true negatives as indeterminate for QFT-G,
when it is applied for active TB diagnosis in a clinically suspected
population. Based on our study results, since the subjects with
.0.25 IU/ml of IFN-c secretion to PHA were able to give valid
QFT-G results, we suggest that the IFN-c level ,0.25 IU/ml
would be a better cut-off point for PHA. However, this needs
further evaluation with a large sample size.
There are some limitations in our study. The diagnosis of active
TB in patients with smear and culture negative results, was made
only by clinical and radiology based methods and they were not
followed up to find their response to anti-TB treatment. Clinical
and radiological evidence have the inherent limitation of
misclassifying other lung diseases as TB, especially in an endemic
setting, which might be one of the reasons for obtaining the low
positivity (65%) for QFT-G. However, similar positivity was
observed among culture confirmed patients. Thus this limitation is
less likely to affect our conclusions. Most of our study patients
(73%) had CD4 count ,200 cells/ml, which is considered as AIDS
defining advanced stage. This might be alternative reason for
obtaining low positivity for QFT-G and TST. The previous study
which evaluated QFT-G in HIV-TB patients from an endemic
country also reported a similar sensitivity (63%) [18]. In addition,
another study from India also showed a low QFT-G sensitivity of
around 70% in active TB patients [31]. Another limitation of our
study is it did not report the specificity of QFT-G in our
population since HIV positive TB negative subjects were not
recruited. In this study, we used QFT-G and not another
commercial IGRA test, T-SPOT. TB. It is reported that T-
SPOT. TB is more sensitive than QFT-G [9,27,32]. Hence,
further studies on the sensitivity of T-SPOT.TB in HIV-TB
patients are needed to assess the role of IGRA in finding active TB
among suspected cases.
Conclusions
To conclude, the QFT-G alone or in combination with TST
cannot be used to exclude the suspicion of active TB among HIV
infected individuals. Considering 65% sensitivity obtained using
QFT-G alone, we suggest that the combination of QFT-G with
any other test which detects active TB disease in the later stage
such as detection of antigen in the urine samples could be better
approach to exclude the active TB disease. In addition, the low
IFN-c cut-off point for PHA in indeterminate results, suggested in
this study (#0.25 IU/ml), may improve the proportion of valid
QFT-G results, when QFT-G is applied to detect active TB cases
among clinically suspected population.
Table 4. Analysis of variance associated with TST positive
results.
Variables N Odd Ratio (95% CI) P
CD4 .200 cells/ml 81 10.881 (1.010–117.277) 0.04
Sex female 105 0.412 (0.084–2.032) 0.276
Age.36 years 105 2.226 (0.603–8.210) 0.230
BMI.18.5 91 0.740 (0.204–2.686) 0.647
EPTB 105 1.263 (0.357–4.464) 0.717
HIV strain I 105 2.079 (0.430–10.051) 0.363
Presence of Oral candidiasis 84 1.112 (0.294–4.212) 0.876
BMI – Body mass index.
N – Number of patients tested.
doi:10.1371/journal.pone.0005718.t004
Table 5. The level of IFN-c secretion in response to PHA in
QFT-G indeterminate subjects.
Subjects Sputum culture results Mitogen – Nil (IU/ml)
1 Negative 0
2 Positive 0.089
3 Positive 0.356
4 Positive 0
5 Negative 0.095
6 Positive 0.073
7 Negative 0.099
8 Negative 0.16
9 Negative 0.121
10 Positive 0.073
11 Positive 0.24
12 Positive 0.021
13 Positive 0.045
14 Positive 0.008
15 Negative 0.1
16 Negative 0.39
17 Positive 0.24
18 Positive 0.06
doi:10.1371/journal.pone.0005718.t005
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